These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 29514901)

  • 1. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.
    Goo J; Jeong Y; Park YS; Yang E; Jung DI; Rho S; Park U; Sung H; Park PG; Choi JA; Seo SH; Cho NH; Lee H; Lee JM; Kim JO; Song M
    Virus Res; 2020 Mar; 278():197863. PubMed ID: 31945421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L
    J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East respiratory syndrome corona virus.
    Abbas AT; El-Kafrawy SA; Tabll AA; Hashem AM; Al Subhi TL; Alsaadi M; Azhar EI
    Hum Antibodies; 2024; 32(3):129-137. PubMed ID: 38758996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein.
    Zhou H; Chen Y; Zhang S; Niu P; Qin K; Jia W; Huang B; Zhang S; Lan J; Zhang L; Tan W; Wang X
    Nat Commun; 2019 Jul; 10(1):3068. PubMed ID: 31296843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus.
    Lee JH; Kim JW; Lee HE; Song JY; Cho AH; Hwang JH; Heo K; Lee S
    Virus Res; 2024 Jul; 345():199383. PubMed ID: 38697296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.
    Ying T; Du L; Ju TW; Prabakaran P; Lau CC; Lu L; Liu Q; Wang L; Feng Y; Wang Y; Zheng BJ; Yuen KY; Jiang S; Dimitrov DS
    J Virol; 2014 Jul; 88(14):7796-805. PubMed ID: 24789777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
    Han HJ; Liu JW; Yu H; Yu XJ
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.
    Niu P; Zhang S; Zhou P; Huang B; Deng Y; Qin K; Wang P; Wang W; Wang X; Zhou J; Zhang L; Tan W
    J Infect Dis; 2018 Sep; 218(8):1249-1260. PubMed ID: 29846635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
    Choi JH; Woo HM; Lee TY; Lee SY; Shim SM; Park WJ; Yang JS; Kim JA; Yun MR; Kim DW; Kim SS; Zhang Y; Shi W; Wang L; Graham BS; Mascola JR; Wang N; McLellan JS; Lee JY; Lee H
    PLoS One; 2020; 15(5):e0232757. PubMed ID: 32384116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans.
    Addetia A; Stewart C; Seo AJ; Sprouse KR; Asiri AY; Al-Mozaini M; Memish ZA; Alshukairi AN; Veesler D
    Cell Rep; 2024 Aug; 43(8):114530. PubMed ID: 39058596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
    Tang XC; Agnihothram SS; Jiao Y; Stanhope J; Graham RL; Peterson EC; Avnir Y; Tallarico AS; Sheehan J; Zhu Q; Baric RS; Marasco WA
    Proc Natl Acad Sci U S A; 2014 May; 111(19):E2018-26. PubMed ID: 24778221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD.
    Wang C; Hua C; Xia S; Li W; Lu L; Jiang S
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.